ArticleClinics (Sao Paulo, Brazil)2026
Genomic insights into uterine leiomyosarcoma: Unraveling KMT2D, CREBBP, NOTCH2, TSC2, ATM, and GNAS signatures.
Article in Clinics (Sao Paulo, Brazil), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uterine Leiomyosarcoma (ULMS), characterized by diagnostic and therapeutic challenges, remains poorly understood despite advancements. Previous research identified genetic mutations in ULMS samples, suggesting their role in pathogenesis. This study deepened the exploration, focusing on specific genes (KMT2D, CREBBP, NOTCH2, ATM, TSC2, GNAS), validating mutations, examining gene methylation, and correlating with clinical features. Thirty samples, including 15 Formalin-Fixed Paraffin-Embedded (FFPE) and 15 fresh-frozen ULMS, were collected, comprising 3 ULMS, 3 Uterine Leiomyomas (ULM), 3 Myometrial samples (MM), and 6 other Uterine Sarcomas (US) for each sample set. Two cell lines, ULM (THESCs - CRL ‒ 4003) and ULMS (SK-UT-1 ‒ HTB-114), were used for comprehensive analysis. FFPE samples underwent genomic DNA extraction using the QIAamp DNA FFPE Tissue Kit, and methylation levels were assessed using the Illumina Infinium Methylation EPIC BeadChip 850k system. Genomic DNA and RNA were extracted using the Trizol method. qRT-PCR with TaqMan assays analyzed gene expression. Mutations in CREBBP, NOTCH2, and GNAS were sequenced using the Sanger method. Results indicated downregulation in CREBBP, GNAS, and NOTCH2 genes in ULMS. Sequencing revealed specific mutations (e.g., c.4063G>A in CREBBP, T>A at position 78 in NOTCH2). A pronounced reduction in CpG region methylation suggested a unique epigenetic alteration in ULMS. Methylation with clinical outcomes identified ATM as a potential independent prognostic biomarker. In conclusion, this study provides a comprehensive view of ULMS molecular complexity, potentially influencing clinical practices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.